OS Therapies ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its OST-HER2 listeria ...
Akeso Inc. (9926.HK) ("Akeso", "the Company") released its 2024 annual report, emphasizing the company's key achievements in drug research, clinical development, and commercialization.
Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today ...
Colorado regulators are issuing licenses for providing psychedelic mushrooms and are planning to authorize the state’s first ...
In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback